Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | GABRP | O00591 | 1/20 | 0.30 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21808534 | 0.91 | CHRNB2 (0.34) | SLC6A1TSHRSLC6A11LMNASMN1; SMN2 | |
| SCHEMBL3174694 | 0.91 | CHRNB2 (0.34) | SLC6A1TSHRSLC6A11LMNASMN1; SMN2 | |
| SCHEMBL1404442 | 0.91 | CHRNB2 (0.34) | SLC6A1TSHRSLC6A11LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6336086 | 0.88 | CHRNB2 (0.33) | SLC6A1TSHRSLC6A11LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL16178433 | 0.88 | CHRNB2 (0.33) | SLC6A1TSHRSLC6A11LMNASMN1; SMN2 | |
| SCHEMBL931097 | 0.83 | RECQL (0.33) | LMNAALDH1A1GLAHPGD | |
| SCHEMBL23406750 | 0.81 | CHRNB2 (0.34) | TSHRLMNACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL22799163 | 0.81 | CHRNB2 (0.34) | TSHRLMNACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL27139 | 0.80 | RECQL (0.32) | LMNAALDH1A1 | |
| SCHEMBL30686962 | 0.78 | SLC6A1 (0.39) | SLC6A1TSHRSLC6A11LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4476221-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | Bayer Aktiengesellschaft (DE) | 2024-12-18 | — | — | EP | disclosed |
| WO-2024238793-A1 | FUSED TRIAZINONES FOR USE IN THE TREATMENT OF CANCER | RGENTA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024215862-A2 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230295123-A1 | NOVEL IMIDAZOLE-PYRAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023152255-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023056951-A1 | ARYL-SUBSTITUTED HETEROCYCLIC COMPOUND | 杭州德睿智药科技有限公司 | 2023-04-13 | — | — | WO | disclosed |
| US-20220402908-A1 | CXCR6 INHIBITORS AND METHODS OF USE | Sanford Burnham Prebys Medical Discovery Institute | 2022-12-22 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | disclosed |
| EP-1984366-A1 | 3, 9-DIAZABICYCLO Ý3.3. 1¨NONANE DERIVATIVES AND THEIR USE AS MONOAMINE?NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007090887-A1 | 3, 9-DIAZABICYCLO [3.3. 1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE?NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SLC6A1 4827/4885TSHR 4359/4885SLC6A11 4836/4885 |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | SLC6A1 4827/4885TSHR 4359/4885SLC6A11 4836/4885 |
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | SLC6A1 3651/4885TSHR 846/4885SLC6A11 3754/4885 |
| US-20230295123-A1 | NOVEL IMIDAZOLE-PYRAZOLE DERIVATIVES | CYP3A7, NISCH, ARG1 | SLC6A1 2272/4885TSHR 659/4885SLC6A11 1785/4885 |
| US-20220402908-A1 | CXCR6 INHIBITORS AND METHODS OF USE | CXCR6, CXCR1, CXCR5 | SLC6A1 2507/4885TSHR 1567/4885SLC6A11 2678/4885 |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SLC6A1 4827/4885TSHR 4359/4885SLC6A11 4836/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SLC6A1 4827/4885TSHR 4359/4885SLC6A11 4836/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | SLC6A1 4827/4885TSHR 4359/4885SLC6A11 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.